Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Source: View publication →
In the phase III ALTA-1L trial, the next-generation ALK inhibitor brigatinib demonstrated superior progression-free survival and delayed worsening of quality of life compared to crizotinib in patients with ALK inhibitor-naive, advanced ALK-positive non-small cell lung cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ALTA-1L trial established brigatinib as a highly efficacious once-daily first-line treatment for advanced ALK-positive NSCLC, offering a dramatic reduction in the risk of disease progression or death compared to the historical standard crizotinib, while also improving health-related quality of life.
Historical Context
Crizotinib, a first-generation TKI, initially revolutionized the treatment of ALK-rearranged NSCLC but was limited by the inevitable development of resistance and poor central nervous system penetration. Brigatinib, a next-generation ALK inhibitor, had previously gained approval for patients progressing on crizotinib. The ALTA-1L trial moved brigatinib into the first-line setting, joining other next-generation inhibitors like alectinib (ALEX trial) in demonstrating overwhelming superiority over crizotinib in newly diagnosed patients.
Guided Discussion
High-yield insights from every perspective
Why is central nervous system (CNS) penetration a critical pharmacokinetic property for next-generation ALK inhibitors like brigatinib compared to the first-generation inhibitor crizotinib in the treatment of ALK-positive NSCLC?
Key Response
ALK-positive NSCLC has a uniquely high propensity for brain metastases. Crizotinib is a known substrate for the P-glycoprotein efflux pump, leading to poor blood-brain barrier penetration; thus, the CNS is a frequent sanctuary site for tumor progression. Next-generation agents like brigatinib were structurally designed to overcome this barrier, which is why ALTA-1L specifically evaluated intracranial progression-free survival.
A patient with newly diagnosed advanced ALK-positive NSCLC presents with asymptomatic brain metastases. Based on the ALTA-1L trial and current standards, why should you choose a next-generation ALK inhibitor like brigatinib over crizotinib, and would you recommend upfront whole-brain radiation?
Key Response
Brigatinib demonstrated superior systemic efficacy and profound intracranial response rates compared to crizotinib. In modern practice, upfront whole-brain radiation is typically deferred in asymptomatic patients due to the high CNS penetration and durable intracranial activity of next-generation ALK inhibitors like brigatinib, sparing the patient from significant neurocognitive toxicity.
In the ALTA-1L trial, brigatinib showed robust efficacy against secondary ALK resistance mutations. How does the molecular profile of resistance to brigatinib inform subsequent therapeutic sequencing, particularly regarding the G1202R solvent-front mutation and the use of third-generation TKIs?
Key Response
Crizotinib typically induces L1196M or G1269A mutations, which second-generation TKIs (brigatinib, alectinib) can target. However, patients progressing on brigatinib often select for the highly refractory G1202R solvent-front mutation. Understanding this acquired resistance mechanism is vital because it justifies sequencing to lorlatinib, a third-generation TKI specifically designed with a macrocyclic structure to overcome G1202R.
Given that alectinib was already established as a first-line standard based on the ALEX trial prior to the ALTA-1L results, how do you weigh the distinct toxicity profiles of brigatinib versus alectinib when making individualized treatment decisions for a newly diagnosed ALK+ patient in the absence of head-to-head data?
Key Response
Attending-level decision-making often hinges on toxicity management. Brigatinib is uniquely associated with early-onset pulmonary events (EOPE) requiring a 7-day lead-in at 90 mg before escalating to 180 mg, as well as CPK elevations and hypertension. Conversely, alectinib is associated with myalgias, edema, and hepatotoxicity. Choosing between these highly effective agents requires matching these specific adverse event profiles with the patient's baseline cardiopulmonary and hepatic comorbidities.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ALTA-1L trial utilized a Blinded Independent Review Committee (BIRC) alongside investigator assessment for its primary endpoint of PFS. In trials with distinct toxicity profiles that essentially unblind investigators, how do discrepancies between investigator and BIRC assessments of complex endpoints like intracranial RANO-BM impact the statistical robustness and interpretation of the primary outcome?
Key Response
In open-label trials where unique adverse events (e.g., brigatinib's EOPE or crizotinib's visual changes) unblind the investigator, ascertainment bias is a major risk. A BIRC mitigates this. If BIRC and investigator PFS diverge significantly, particularly in subjective or complex neuro-radiological assessments, it raises methodological questions regarding censoring rules, informative dropout, and the true effect size of the intervention.
This paper presents a 'Second Interim Analysis' of the ALTA-1L trial. As a critical editor, what are the methodological and ethical hazards of publishing multiple interim analyses based on progression-free survival before final overall survival (OS) data matures, and how does this affect trial integrity?
Key Response
Publishing multiple interim analyses based on early PFS signals can rapidly alter the standard of care, which is clinically beneficial but methodologically perilous. It often leads to massive patient crossover, thereby confounding the final OS endpoint. An editor must scrutinize the alpha-spending function (e.g., O'Brien-Fleming boundaries), ensure statistical rigor for early reporting, and prevent the early data from inappropriately closing the window to observe long-term safety signals.
How does the evidence from the ALTA-1L trial impact ASCO and NCCN guideline recommendations for the first-line treatment of ALK-positive NSCLC, specifically in categorizing brigatinib, alectinib, and lorlatinib as 'preferred' regimens compared to crizotinib?
Key Response
Based on ALTA-1L's demonstration of superior PFS and intracranial efficacy, guidelines like NCCN elevated brigatinib to a Category 1, preferred first-line option. The committee uses this Level 1 evidence to definitively relegate crizotinib to historical use. The ongoing challenge for guideline committees is determining the exact hierarchy among the preferred agents (brigatinib, alectinib, lorlatinib) since trials like ALTA-1L, ALEX, and CROWN all used crizotinib as the comparator rather than another next-generation TKI.
Clinical Landscape
Noteworthy Related Trials
PROFILE 1014
Tested
Crizotinib 250mg twice daily
Population
Treatment-naive advanced ALK-positive NSCLC
Comparator
Platinum-based chemotherapy
Endpoint
Progression-free survival (PFS)
ALEX Trial
Tested
Alectinib 600mg twice daily
Population
Treatment-naive advanced ALK-positive NSCLC
Comparator
Crizotinib 250mg twice daily
Endpoint
Progression-free survival (PFS)
CROWN Trial
Tested
Lorlatinib 100mg daily
Population
Treatment-naive advanced ALK-positive NSCLC
Comparator
Crizotinib 250mg twice daily
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis